Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Incannex Healthcare (IXHL) Research & Development (2021 - 2025)

Incannex Healthcare's Research & Development history spans 3 years, with the latest figure at $2.3 million for Q4 2025.

  • On a quarterly basis, Research & Development rose 61.24% to $2.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $9.8 million, a 17.65% decrease, with the full-year FY2025 number at $10.7 million, down 16.55% from a year prior.
  • Research & Development hit $2.3 million in Q4 2025 for Incannex Healthcare, up from $1.1 million in the prior quarter.
  • Over the last five years, Research & Development for IXHL hit a ceiling of $4.4 million in Q2 2024 and a floor of $1.1 million in Q3 2025.
  • Historically, Research & Development has averaged $2.7 million across 3 years, with a median of $2.7 million in 2023.
  • The widest YoY moves for Research & Development: up 61.24% in 2025, down 61.33% in 2025.
  • Tracing IXHL's Research & Development over 3 years: stood at $2.6 million in 2023, then crashed by 46.4% to $1.4 million in 2024, then surged by 61.24% to $2.3 million in 2025.
  • Business Quant data shows Research & Development for IXHL at $2.3 million in Q4 2025, $1.1 million in Q3 2025, and $3.7 million in Q2 2025.